Pluri Inc. (PluriStem Therapeutics Inc.) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 6, 2009, by PluriStem Therapeutics Inc., a Nevada corporation headquartered in Haifa, Israel. The report discloses a material definitive agreement entered into on May 5, 2009, regarding a private placement of securities.
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction rather than standard operating financial metrics. Key terms include:
- Securities Issued: 888,406 shares of Common Stock and Warrants to purchase 488,623 shares of Common Stock.
- Unit Price: $1.50 per Unit (Common Stock + Warrants).
- Warrant Exercise Price: $1.96 per share.
- Warrant Terms: Exercisable for five years, commencing six months after issuance.
- Placement Agent: Rodman & Renshaw, LLC.
- Agent Compensation: 6% cash fee of the gross purchase price plus warrants to purchase 53,304 shares at an exercise price of $1.875.
Material Changes
The primary material change is the entry into securities purchase agreements with two investors. The transaction is expected to close no later than May 8, 2009. The offering was conducted pursuant to a shelf registration statement on Form S-3 (File No. 333-151761).
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future operations, or a discussion of risks beyond the standard incorporation of the warrant and purchase agreement terms by reference. The document notes that the description of the Warrants is a summary and is qualified in its entirety by reference to Exhibit 4.1.
Investor Verification Checklist
- Verify the actual closing date of the transaction (scheduled for no later than May 8, 2009).
- Review Exhibit 4.1 for the full legal terms and conditions of the Warrants.
- Review Exhibit 10.1 for the full Securities Purchase Agreement.
- Confirm the total gross proceeds raised based on the final number of Units sold.
- Check subsequent filings for the impact of this dilution on existing shareholders.